A Phase 1 interventional study of Idelalisib and Ruxolitinib in Myelofibrosis, sponsored by Gilead Sciences. Terminated at 2 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-09-16.
Sponsored by Gilead Sciences · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 50 studies testing ruxolitinib in Primary Myelofibrosis — 8 open to participants now, 15 under way, 1 of them phase 3. ruxolitinib · Primary Myelofibrosis.
Among the 50 studies testing ruxolitinib in Primary Myelofibrosis, this one is the 43rd largest by enrollment, is one of 4 that started in 2015, is one of 12 in phase 1, and was the 23rd registered.
627 studies on the registry are indexed under Primary Myelofibrosis; 125 are open to participants now.
Browse Primary Myelofibrosis studies →8 of the 50 studies testing ruxolitinib in Primary Myelofibrosis are open now, in 1 country. Recruiting first, the newest first:
University of Utah · Sites in United States
Ages 18+
Fred Hutchinson Cancer Center · Sites in United States
Ages 18–75
M.D. Anderson Cancer Center · Sites in United States
Ages 18+
Memorial Sloan Kettering Cancer Center · Sites in United States
Ages 18+
M.D. Anderson Cancer Center · Sites in United States
Ages 18–75
By country, each count listing its studies:
ruxolitinib: first FDA approval 2011 (JAKAFI), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →
Of the 102 Primary Myelofibrosis studies recruiting now, 84 (82%) set no upper age limit and 13 (13%) stop at 75 or younger; 10 take children under 18; 7 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
50 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 20 · Phase 2 27 · Phase 3 6 · Phase 4 4
First in 2007; this study’s year is marked. 4 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 10 is below the median of 43 across 490 interventional studies indexed under Primary Myelofibrosis.
Median enrollment 45 across the 50 interventional studies. Of the 32 that completed or were terminated, 23 (72%) have results posted.
This tab as a report to print or save as PDF → With an account.
20 of 50 have an industry lead sponsor. The 10 most frequent:
Gilead Sciences is the lead sponsor of 692 studies on the registry; 26 are open to participants now.
Of its 261 completed or terminated interventional studies of FDA-regulated products, 251 (96%) have results posted.
Gilead Sciences has 2 studies filed under Primary Myelofibrosis — fewer than ten, so there is no comparison to draw.
6 of the studies testing ruxolitinib in Primary Myelofibrosis that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04041050AbbVieA Study Evaluating Safety and Tolerability, and Pharmacokinetics of Navitoclax Monotherapy and in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasm | 2026-12-31 |
| NCT05714072Memorial Sloan Kettering Cancer CenterA Study of Ruxolitinib in Combination With Abemaciclib for the Treatment of Myelofibrosis | 2027-01 |
| NCT06345495M.D. Anderson Cancer CenterHigh Dose Ruxolitinib and Allogeneic Stem Cell Transplantation in Myelofibrosis Patients With Splenomegaly | 2027-01-01 |
| NCT05371964Geron CorporationA Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination With Ruxolitinib in Participants With Myelofibrosis | 2027-02 |
| NCT03069326Memorial Sloan Kettering Cancer CenterA Clinical Study to Test the Effects of Ruxolitinib And Thalidomide Combination for Patients With Myelofibrosis | 2027-02 |
Add all 6 to your calendar (.ics) → With an account.
Among the 50 studies testing ruxolitinib in Primary Myelofibrosis, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The primary objective of this study is to evaluate the safety, tolerability, and pharmacokinetics of idelalisib in adults receiving ruxolitinib as therapy for intermediate to high-risk primary myelofibrosis (PMF), post-polycythemia vera, or post-essential thrombocythemia myelofibrosis (post-PV MF or post-ET MF) with progressive or relapsed disease.
This is a dose-escalation study. There will be 4 cohorts (A, B, C, D). Participants will receive an escalating dose or dose frequency of idelalisib based on the safety data of available cohort(s).
Key Inclusion Criteria:
Key Exclusion Criteria:
NOTE: Other protocol defined Inclusion/ Exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CTCAE grade
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Idelalisib 50 mg once daily in participants receiving ruxolitinib.
Drug: Idelalisib · Drug: Ruxolitinib
Idelalisib 50 mg twice daily in participants receiving ruxolitinib.
Drug: Idelalisib · Drug: Ruxolitinib
Idelalisib 150 mg once daily in participants receiving ruxolitinib.
Drug: Idelalisib · Drug: Ruxolitinib
Idelalisib 150 mg twice daily in participants receiving ruxolitinib.
Drug: Idelalisib · Drug: Ruxolitinib
Idelalisib tablets administered orally for 24 weeks
Also known as: Zydelig®, CAL-101, GS-1101
Ruxolitinib will be administered per standard of care according to package insert
Percentage of Participants Experiencing Any Treatment Emergent Adverse Events Within 28 Days of Idelalisib Exposure
Time frame: First dose date up to 28 days
Percentage of Participants Experiencing Adverse Events Related to Idelalisib Within 28 Days of Idelalisib Exposure
Time frame: First dose date up to 28 days
Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities Within 28 Days of Idelalisib Exposure by Worst Grade at Postbaseline
Treatment-emergent laboratory abnormalities were defined as values that increase at least one toxicity grade from baseline. The most severe graded abnormality from all tests was counted for each participant. Treatment-emergent laboratory abnormalities were graded per Common Terminology Criteria for Adverse Events (CTCAE), Version 4.03 where 1=Mild, 2=Moderate, 3=Severe, 4=Potentially Life Threatening.
Time frame: First dose date up to 28 days
Percentage of Participants Who Permanently Discontinued Idelalisib Due to an Adverse Event Within 28 Days of Idelalisib Exposure
Time frame: First dose date up to 28 days
Percentage of Participants Experiencing Treatment Emergent Adverse Events Beyond 28 Days of Idelalisib Exposure
Time frame: First dose date up to the last dose date (maximum:15.1 months) plus 30 days
Percentage of Participants Experiencing Adverse Events Related to Idelalisib Beyond 28 Days of Idelalisib Exposure
Time frame: First dose date up to the last dose date (maximum:15.1 months) plus 30 days
Percentage of Participants Experiencing Abnormal Laboratory Abnormalities Beyond 28 Days of Idelalisib Exposure by Worst Grade at Postbaseline
Treatment-emergent laboratory abnormalities were defined as values that increase at least one toxicity grade from baseline. The most severe graded abnormality from all tests was counted for each participant. Treatment-emergent laboratory abnormalities were graded per Common Terminology Criteria for Adverse Events (CTCAE), Version 4.03 where 1=Mild, 2=Moderate, 3=Severe, 4=Potentially Life Threatening.
Time frame: First dose date up to the last dose date (maximum:15.1 months) plus 30 days
Percentage of Participants Who Permanently Discontinued Idelalisib Due to an Adverse Event Beyond 28 Days of Exposure
Time frame: First dose date up to the last dose date (maximum:15.1 months) plus 30 days
Rate of Overall Response
Rate of overall response as defined by 2013 Revised International Working Group for Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European Leukemia Net (ELN) response criteria.
Time frame: Start of treatment to end of treatment ( up to 15.1 months)
Plasma Concentration of Idelalisib and GS-563117 (Idelalisib Metabolite)
Time frame: Predose Week 2, 1.5 hour Week 2, and Predose Week 3
Participants were enrolled at study sites in the United States. The first participant was screened on 05 June 2015. The last study visit occurred on 20 November 2017.
| Milestone | Cohort A, Idelalisib + Ruxolitinib | Cohort B, Idelalisib + Ruxolitinib |
|---|---|---|
| Started | 6 | 4 |
| Completed | 0 | 0 |
| Not completed | 6 | 4 |
| Withdrew: Progressive disease | 3 | 1 |
| Withdrew: Investigator discretion | 1 | 2 |
| Withdrew: Adverse event | 1 | 0 |
| Withdrew: Withdrawal by participant | 1 | 0 |
| Withdrew: Study terminated by sponsor | 0 | 1 |
| Percentage of participants | Cohort A, Idelalisib + Ruxolitinib | Cohort B, Idelalisib + Ruxolitinib |
|---|---|---|
| Percentage of Participants Experiencing Any Treatment Emergent Adverse Events Within 28 Days of Idelalisib Exposure | 100.0 | 75.0 |
| Percentage of participants | Cohort A, Idelalisib + Ruxolitinib | Cohort B, Idelalisib + Ruxolitinib |
|---|---|---|
| Percentage of Participants Experiencing Adverse Events Related to Idelalisib Within 28 Days of Idelalisib Exposure | 33.3 | 0 |
Treatment-emergent laboratory abnormalities were defined as values that increase at least one toxicity grade from baseline. The most severe graded abnormality from all tests was counted for each participant. Treatment-emergent laboratory abnormalities were graded per Common Terminology Criteria for Adverse Events (CTCAE), Version 4.03 where 1=Mild, 2=Moderate, 3=Severe, 4=Potentially Life Threatening.
| Percentage of participants | Cohort A, Idelalisib + Ruxolitinib | Cohort B, Idelalisib + Ruxolitinib |
|---|---|---|
| Anemia (Grade 1) | 0 | 0 |
| Anemia (Grade 2) | 0 | 0 |
| Anemia (Grade 3) | 16.7 | 25.0 |
| Anemia (Grade 4) | 0 | 0 |
| White blood cell decreased (Grade 1) | 0 | 0 |
| White blood cell decreased (Grade 2) | 0 | 25.0 |
| White blood cell decreased (Grade 3) | 0 | 0 |
| White blood cell decreased (Grade 4) | 0 | 0 |
| Lymphocyte count decreased (Grade 1) | 0 | 0 |
| Lymphocyte count decreased (Grade 2) | 33.3 | 0 |
| Lymphocyte count decreased (Grade 3) | 16.7 | 25.0 |
| Lymphocyte count decreased (Grade 4) | 0 | 0 |
| Lymphocyte count increased (Grade 1) | 0 | 0 |
| Lymphocyte count increased (Grade 2) | 16.7 | 0 |
| Lymphocyte count increased (Grade 3) | 0 | 0 |
| Lymphocyte count increased (Grade 4) | 0 | 0 |
| Neutrophil count decreased (Grade 1) | 0 | 0 |
| Neutrophil count decreased (Grade 2) | 0 | 25.0 |
| Neutrophil count decreased (Grade 3) | 0 | 0 |
| Neutrophil count decreased (Grade 4) | 0 | 0 |
| Platelet count decreased (Grade 1) | 0 | 25.0 |
| Platelet count decreased (Grade 2) | 0 | 25.0 |
| Platelet count decreased (Grade 3) | 16.7 | 0 |
| Platelet count decreased (Grade 4) | 0 | 0 |
| Alanine aminotransferase increased (Grade 1) | 16.7 | 25.0 |
| Alanine aminotransferase increased (Grade 2) | 0 | 0 |
| Alanine aminotransferase increased (Grade 3) | 0 | 0 |
| Alanine aminotransferase increased (Grade 4) | 0 | 0 |
| Hypocalcemia (Grade 1) | 0 | 25.0 |
| Hypocalcemia (Grade 2) | 0 | 25.0 |
| Hypocalcemia (Grade 3) | 0 | 0 |
| Hypocalcemia (Grade 4) | 0 | 0 |
| Aspartate aminotransferase increased (Grade 1) | 33.3 | 25.0 |
| Aspartate aminotransferase increased (Grade 2) | 0 | 0 |
| Aspartate aminotransferase increased (Grade 3) | 0 | 0 |
| Aspartate aminotransferase increased (Grade 4) | 0 | 0 |
| Blood bilirubin increased (Grade 1) | 16.7 | 0 |
| Blood bilirubin increased (Grade 2) | 0 | 0 |
| Blood bilirubin increased (Grade 3) | 0 | 0 |
| Blood bilirubin increased (Grade 4) | 0 | 0 |
| Creatinine increased (Grade 1) | 16.7 | 50.0 |
| Creatinine increased (Grade 2) | 0 | 0 |
| Creatinine increased (Grade 3) | 0 | 0 |
| Creatinine increased (Grade 4) | 0 | 0 |
| Gamma Glutamyl Transferase Increased (Grade 1) | 16.7 | 0 |
| Gamma Glutamyl Transferase Increased (Grade 2) | 0 | 25.0 |
| Gamma Glutamyl Transferase Increased (Grade 3) | 0 | 0 |
| Gamma Glutamyl Transferase Increased (Grade 4) | 0 | 0 |
| Hypoglycemia (Grade 1) | 16.7 | 0 |
| Hypoglycemia (Grade 2) | 0 | 0 |
| Hypoglycemia (Grade 3) | 0 | 0 |
| Hypoglycemia (Grade 4) | 0 | 0 |
| Hypomagnesemia (Grade 1) | 0 | 25.0 |
| Hypomagnesemia (Grade 2) | 0 | 0 |
| Hypomagnesemia (Grade 3) | 0 | 0 |
| Hypomagnesemia (Grade 4) | 0 | 0 |
| Hyperkalemia (Grade 1) | 0 | 0 |
| Hyperkalemia (Grade 2) | 16.7 | 0 |
| Hyperkalemia (Grade 3) | 0 | 0 |
| Hyperkalemia (Grade 4) | 0 | 0 |
| Hyperuricemia (Grade 1) | 33.3 | 25.0 |
| Hyperuricemia (Grade 2) | 0 | 0 |
| Hyperuricemia (Grade 3) | 0 | 0 |
| Hyperuricemia (Grade 4) | 16.7 | 0 |
| Percentage of participants | Cohort A, Idelalisib + Ruxolitinib | Cohort B, Idelalisib + Ruxolitinib |
|---|---|---|
| Percentage of Participants Who Permanently Discontinued Idelalisib Due to an Adverse Event Within 28 Days of Idelalisib Exposure | 0.0 | 0.0 |
| Percentage of participants | Cohort A, Idelalisib + Ruxolitinib | Cohort B, Idelalisib + Ruxolitinib |
|---|---|---|
| Percentage of Participants Experiencing Treatment Emergent Adverse Events Beyond 28 Days of Idelalisib Exposure | 100.0 | 100.0 |
| Percentage of participants | Cohort A, Idelalisib + Ruxolitinib | Cohort B, Idelalisib + Ruxolitinib |
|---|---|---|
| Percentage of Participants Experiencing Adverse Events Related to Idelalisib Beyond 28 Days of Idelalisib Exposure | 50.0 | 25.0 |
Treatment-emergent laboratory abnormalities were defined as values that increase at least one toxicity grade from baseline. The most severe graded abnormality from all tests was counted for each participant. Treatment-emergent laboratory abnormalities were graded per Common Terminology Criteria for Adverse Events (CTCAE), Version 4.03 where 1=Mild, 2=Moderate, 3=Severe, 4=Potentially Life Threatening.
| Percentage of participants | Cohort A, Idelalisib + Ruxolitinib | Cohort B, Idelalisib + Ruxolitinib |
|---|---|---|
| Anemia (Grade 1) | 0 | 0 |
| Anemia (Grade 2) | 0 | 0 |
| Anemia (Grade 3) | 33.3 | 25.0 |
| Anemia (Grade 4) | 0 | 0 |
| White blood cell decreased (Grade 1) | 16.7 | 0 |
| White blood cell decreased (Grade 2) | 0 | 25.0 |
| White blood cell decreased (Grade 3) | 16.7 | 0 |
| White blood cell decreased (Grade 4) | 0 | 0 |
| Lymphocyte count decreased (Grade 1) | 0 | 0 |
| Lymphocyte count decreased (Grade 2) | 0 | 25.0 |
| Lymphocyte count decreased (Grade 3) | 50.0 | 50.0 |
| Lymphocyte count decreased (Grade 4) | 16.7 | 0 |
| Lymphocyte count increased (Grade 1) | 0 | 0 |
| Lymphocyte count increased (Grade 2) | 33.3 | 25.0 |
| Lymphocyte count increased (Grade 3) | 0 | 0 |
| Lymphocyte count increased (Grade 4) | 0 | 0 |
| Neutrophil count decreased (Grade 1) | 0 | 0 |
| Neutrophil count decreased (Grade 2) | 0 | 0 |
| Neutrophil count decreased (Grade 3) | 16.7 | 25.0 |
| Neutrophil count decreased (Grade 4) | 0 | 0 |
| Platelet count decreased (Grade 1) | 0 | 25.0 |
| Platelet count decreased (Grade 2) | 16.7 | 25.0 |
| Platelet count decreased (Grade 3) | 16.7 | 25.0 |
| Platelet count decreased (Grade 4) | 0 | 25.0 |
| Alanine aminotransferase increased (Grade 1) | 16.7 | 25.0 |
| Alanine aminotransferase increased (Grade 2) | 0 | 25.0 |
| Alanine aminotransferase increased (Grade 3) | 0 | 25.0 |
| Alanine aminotransferase increased (Grade 4) | 0 | 0 |
| Hypocalcemia (Grade 1) | 0 | 25.0 |
| Hypocalcemia (Grade 2) | 0 | 25.0 |
| Hypocalcemia (Grade 3) | 0 | 0 |
| Hypocalcemia (Grade 4) | 0 | 0 |
| Alkaline phosphatase increased (Grade 1) | 16.7 | 0 |
| Alkaline phosphatase increased (Grade 2) | 0 | 0 |
| Alkaline phosphatase increased (Grade 3) | 0 | 0 |
| Alkaline phosphatase increased (Grade 4) | 0 | 0 |
| Aspartate aminotransferase increased (Grade 1) | 50.0 | 50.0 |
| Aspartate aminotransferase increased (Grade 2) | 0 | 25.0 |
| Aspartate aminotransferase increased (Grade 3) | 0 | 0 |
| Aspartate aminotransferase increased (Grade 4) | 0 | 0 |
| Blood bilirubin increased (Grade 1) | 33.3 | 25.0 |
| Blood bilirubin increased (Grade 2) | 0 | 0 |
| Blood bilirubin increased (Grade 3) | 0 | 0 |
| Blood bilirubin increased (Grade 4) | 0 | 0 |
| Creatinine increased (Grade 1) | 16.7 | 50.0 |
| Creatinine increased (Grade 2) | 0 | 0 |
| Creatinine increased (Grade 3) | 0 | 0 |
| Creatinine increased (Grade 4) | 0 | 0 |
| Gamma Glutamyl Transferase Increased (Grade 1) | 50.0 | 25.0 |
| Gamma Glutamyl Transferase Increased (Grade 2) | 0 | 25.0 |
| Gamma Glutamyl Transferase Increased (Grade 3) | 16.7 | 50.0 |
| Gamma Glutamyl Transferase Transferase (Grade 4) | 0 | 0 |
| Hyperglycemia (Grade 1) | 0 | 0 |
| Hyperglycemia (Grade 2) | 0 | 0 |
| Hyperglycemia (Grade 3) | 0 | 25.0 |
| Hyperglycemia (Grade 4) | 0 | 0 |
| Hypoglycemia (Grade 1) | 16.7 | 0 |
| Hypoglycemia (Grade 2) | 0 | 0 |
| Hypoglycemia (Grade 3) | 0 | 0 |
| Hypoglycemia (Grade 4) | 0 | 0 |
| Hypomagnesemia (Grade 1) | 0 | 25.0 |
| Hypomagnesemia (Grade 2) | 0 | 0 |
| Hypomagnesemia (Grade 3) | 0 | 0 |
| Hypomagnesemia (Grade 4) | 0 | 0 |
| Hyperkalemia (Grade 1) | 0 | 25.0 |
| Hyperkalemia (Grade 2) | 16.7 | 0 |
| Hyperkalemia (Grade 3) | 0 | 0 |
| Hyperkalemia (Grade 4) | 0 | 0 |
| Hypokalemia (Grade 1) | 0 | 25.0 |
| Hypokalemia (Grade 2) | 0 | 0 |
| Hypokalemia (Grade 3) | 0 | 0 |
| Hypokalemia (Grade 4) | 0 | 0 |
| Hyponatremia (Grade 1) | 0 | 0 |
| Hyponatremia (Grade 2) | 0 | 0 |
| Hyponatremia (Grade 3) | 0 | 25.0 |
| Hyponatremia (Grade 4) | 0 | 0 |
| Hyperuricemia (Grade 1) | 33.3 | 0 |
| Hyperuricemia (Grade 2) | 0 | 0 |
| Hyperuricemia (Grade 3) | 0 | 0 |
| Hyperuricemia (Grade 4) | 16.7 | 25.0 |
| Percentage of participants | Cohort A, Idelalisib + Ruxolitinib | Cohort B, Idelalisib + Ruxolitinib |
|---|---|---|
| Percentage of Participants Who Permanently Discontinued Idelalisib Due to an Adverse Event Beyond 28 Days of Exposure | 16.7 | 25.0 |
Rate of overall response as defined by 2013 Revised International Working Group for Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European Leukemia Net (ELN) response criteria.
No measurements were reported for this outcome.
| ng/mL | Cohort A, Idelalisib + Ruxolitinib | Cohort B, Idelalisib + Ruxolitinib |
|---|---|---|
| Idelalisib: Predose Week 2 | 9.95 ± 6.534 | 106.83 ± 107.549 |
| Idelalisib: 1.5 hour Postdose Week 2 | 835.00 ± 487.102 | 760.25 ± 438.644 |
| Idelalisib: Predose Week 3 | 6.67 ± 1.770 | 90.25 ± 85.374 |
| GS-563117: Predose Week 2 | 396.6 ± 406.95 | 1156.8 ± 1252.69 |
| GS-563117: 1.5 hour Postdose Week 2 | 1051.4 ± 692.36 | 1405.5 ± 1228.45 |
| GS-563117: Predose Week 3 | 227.9 ± 212.10 | 988.0 ± 1018.05 |
Collected over First dose date up to the last dose date (maximum:15.1 months) plus 30 days. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Cohort A, Idelalisib + Ruxolitinib | 0/6 (0%) | 3/6 (50%) | 6/6 (100%) |
| Cohort B, Idelalisib + Ruxolitinib | 0/4 (0%) | 0/4 (0%) | 4/4 (100%) |
| Event | Cohort A, Idelalisib + Ruxolitinib | Cohort B, Idelalisib + Ruxolitinib |
|---|---|---|
| Febrile neutropeniaBlood and lymphatic system disorders | 1/6 | 0/4 |
| Abdominal painGastrointestinal disorders | 1/6 | 0/4 |
| NauseaGastrointestinal disorders | 1/6 | 0/4 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 1/6 | 0/4 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 1/6 | 0/4 |
| Event | Cohort A, Idelalisib + Ruxolitinib | Cohort B, Idelalisib + Ruxolitinib |
|---|---|---|
| DiarrhoeaGastrointestinal disorders | 2/6 | 2/4 |
| NauseaGastrointestinal disorders | 0/6 | 2/4 |
| FatigueGeneral disorders | 3/6 | 0/4 |
| Urinary tract infectionInfections and infestations | 0/6 | 2/4 |
| MyalgiaMusculoskeletal and connective tissue disorders | 3/6 | 0/4 |
| CoughRespiratory, thoracic and mediastinal disorders | 3/6 | 1/4 |
| Night sweatsSkin and subcutaneous tissue disorders | 1/6 | 2/4 |
| PruritusSkin and subcutaneous tissue disorders | 0/6 | 2/4 |
| *AnaemiaBlood and lymphatic system disorders | 2/6 | 0/4 |
| Abdominal pain upperGastrointestinal disorders | 2/6 | 0/4 |
Full Analysis Set included all participants who took at least 1 dose of study drug.
| Age, Continuous(years) | Cohort A, Idelalisib + Ruxolitinib | Cohort B, Idelalisib + Ruxolitinib | Total |
|---|---|---|---|
| Mean | 62 ± 10.5 | 69 ± 6.1 | 65 ± 9.1 |
| Sex: Female, Male(Participants) | Cohort A, Idelalisib + Ruxolitinib | Cohort B, Idelalisib + Ruxolitinib | Total |
|---|---|---|---|
| Female | 0 | 2 | 2 |
| Male | 6 | 2 | 8 |
| Race/Ethnicity, Customized(Participants) | Cohort A, Idelalisib + Ruxolitinib | Cohort B, Idelalisib + Ruxolitinib | Total |
|---|---|---|---|
| White | 5 | 3 | 8 |
| Others | 1 | 1 | 2 |
| Race/Ethnicity, Customized(Participants) | Cohort A, Idelalisib + Ruxolitinib | Cohort B, Idelalisib + Ruxolitinib | Total |
|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 |
| Not Hispanic or Latino | 6 | 4 | 10 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Jun 2015 to primary completion in Nov 2017, 29 months.
Results were first posted in Aug 2020, 2 years 8 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Aug 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Idelalisib · Ruxolitinib